The DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Drug resistance in ovarian cancer: from mechanism to clinical trial
Open accessAbstract
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian cancer. Continuing to classify drug resistance according to drug type without understanding the underlying mechanisms is unsuitable for current clinical practice. We reviewed the literature regarding various drug resistance mechanisms in ovarian cancer and found that the main resistance mechanisms are as follows: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic modifications. DNA methylation, histone modifications and noncoding RNA activity, three key classes of epigenetic modifications, constitute pivotal mechanisms of drug resistance. One drug can have multiple resistance mechanisms. Moreover, common chemotherapies and targeted drugs may have cross (overlapping) resistance mechanisms. MicroRNAs (miRNAs) can interfere with and thus regulate the abovementioned pathways. A subclass of miRNAs, “epi-miRNAs”, can modulate epigenetic regulators to impact therapeutic responses. Thus, we also reviewed the regulatory influence of miRNAs on resistance mechanisms. Moreover, we summarized recent phase I/II clinical trials of novel drugs for ovarian cancer based on the abovementioned resistance mechanisms. A multitude of new therapies are under evaluation, and the preliminary results are encouraging. This review provides new insight into the classification of drug resistance mechanisms in ovarian cancer and may facilitate in the successful treatment of resistant ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–225 of 225
Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine
Kandettu, A., Adiga, D., Devi, V., Suresh, P. S., Chakrabarty, S., Radhakrishnan, R. A., & Kabekkodu, S. P. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.026 · Cited by 22
Lombardi, R., Sonego, M., Pucci, B., Addi, L., Iannelli, F., Capone, F., Alfano, L., Roca, M. S., Milone, M. R., Moccia, T., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12883 · Cited by 20
Peraza-Vega, R. I., Valverde, M., & Rojas, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063231 · Cited by 20
Dunn, E., Chitcholtan, K., Sykes, P. H., & Garrill, A. (2022) · Cancers · doi:10.3390/cancers14020395 · Cited by 19
DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma
Chen, M., Huang, B., Zhu, L., Wang, Q., Pang, Y. K., Cheng, M., Lian, H., Liu, M., Zhao, K., Xu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875648 · Cited by 19
The progress of peptide vaccine clinical trials in gynecologic oncology
Tang, M., Cai, J., Diao, H., Guo, W., Yang, X., & Xing, S. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2062982 · Cited by 19
Cancer drug resistance related microRNAs: recent advances in detection methods
Hu, X., Song, Z., Yang, Z.-W., Li, J., Liu, J., & Wang, H. (2022) · The Analyst · doi:10.1039/d2an00171c · Cited by 19
Self-citationSilva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., Treacy, A. D., Martin, T., Shaw, J., Doran, P., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34496 · Cited by 18
Epigenetic Markers of Ovarian Cancer
Barton, C. A., Clark, S. J., Hacker, N. F., & O’Brien, P. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_4 · Cited by 17
Hoarau-Véchot, J., Blot-Dupin, M., Pauly, L., Touboul, C., Rafii, S., Rafii, A., & Pasquier, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214173 · Cited by 16
Václavíková, R., Klajic, J., Brynychová, V., Elsnerová, K., Alnæs, G. G., Tost, J., Kristensen, V. N., Rob, L., Kodet, R., Škapa, P., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7186 · Cited by 15
Mo, J., Ruan, S., Yang, B., Jin, Y., Liu, K., Luo, X., & Jiang, H. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200272 · Cited by 15
Fang, Y., Zhao, J., Guo, X., Dai, Y. E., Zhang, H., Yin, F., Zhang, X., Sun, C., Han, Z., Wang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.947252 · Cited by 13
Self-citationYi, C., & Yu, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.893846 · Cited by 12
Li, X., Gao, X., Yuan, J., Wang, F., Xu, X., Wang, C., Liu, H., Guan, W., Zhang, J., & Xu, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.950345 · Cited by 11
Shang, B., Jia, Y., Chen, G., & Wang, Z. (2017) · Respiratory Research · doi:10.1186/s12931-017-0545-6 · Cited by 10
Alghamian, Y., Soukkarieh, C., Abbady, A. Q., & Murad, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-11634-6 · Cited by 10
Liang, S., Liu, Y.-Y., He, J., Gao, T. M., Li, L., & He, S. (2022) · Bioengineered · doi:10.1080/21655979.2022.2064652 · Cited by 9
Qi, X., Li, Y., Liu, W., Wang, Y., Chen, Z., & Lizhu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921385 · Cited by 9
Self-citationDHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines.
Michalak, M., Lach, M., Borska, S., Nowakowski, B., Umezawa, K., & Suchorska, W. M. (2021) · PubMed Central · Cited by 8
Classen, S., Rahlf, E., Jungwirth, J., Albers, N., Hebestreit, L. P., Zielinski, A., Poole, L., Groth, M., Koch, P., Liehr, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113363 · Cited by 7
Morrone, M. D. S., Somensi, N., Franz, L., Ramos, V. D. M., Gasparotto, J., da Rosa, H. T., Sartori, M., Figueiró, F., Gelain, D. P., Zanotto‐Filho, A., et al. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03605-9 · Cited by 6
Trivedi, M. S., Arber, N., Friedman, E., Garber, J. E., Holcomb, K., Horowitz, N. S., Wright, J. D., Lee, J. J., Vornik, L. A., Abutaseh, S., et al. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0051 · Cited by 6
Meng, Y. G., Wu, Q., Zhang, M., Lai, M., Chen, W., Yang, J., Li, J., & Cao, J. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200405 · Cited by 5
Hater, N., Iwaniuk, K. M., Leifeld, C., Grüten, P., Wiek, C., Raba, K., Zhang, F., Fischer, J., Andreassen, P. R., Hanenberg, H., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac177 · Cited by 2
Metadata
- Authors
- Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., & Zou, D.
- Venue
- Molecular Cancer
- Published
- 2024-03-28
- Volume
- 23
- Issue
- 1
- Pages
- 66-66
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W4393275890
- Cited by
- 255
- References
- 225
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.